Valuation dashboard for IGC Pharma, Inc. (IGC) with P/E N/A, P/B 4.20, EV/EBITDA -3.89 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage.
Analysis Summary
IGC Pharma, Inc. reported revenue of $1.2M in the most recent fiscal year, growing at a 5-year CAGR of 5.7%.
Trailing-twelve-month margins: gross margin 21.9%, operating margin -9.9%, net margin -7.0%.
At the current price of $0.27, IGC has negative trailing earnings (P/E not meaningful) and an ROE of -113.58%. Market capitalisation stands at $27M.
Balance sheet quality for IGC: current ratio of 0.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.20 |
| EV / EBITDA | -3.89 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IGC | IGC Pharma, Inc. | $27M | 4.20 | -113.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.27 |
| Market Cap | $27M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | -113.58% |
| Return on Invested Capital | -153.62% |
| Return on Assets | -83.03% |
| Gross Margin | 21.91% |
| Operating Margin | -986.82% |
| Net Margin | -702.14% |
Related companies: ANTX · BOLD · INTS · ITRM · NTRB · NXTC · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IGC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks